Helen Torley
CIK 1528185 · PRESIDENT AND CEO · last filed 2026-10-08
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
HTI price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SAN DIEGO, CA 92130
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| HALO | PRESIDENT AND CEO | 782,970 | $100.76 | $78.89M | -$19.48M | 4 | 2026-10-08 |
| HTI | PRESIDENT AND CEO | 767,780 | — | — | -$83.25M | 89 | 2026-06-03 |
| DGX | Director | 6,260 | $258.65 | $1.62M | $0 | 7 | 2021-05-25 |
| Relypsa Inc (RLYP) Delisted | Director | 0 | — | — | -$19.6K | 5 | 2016-09-02 |
| ONYX PHARMACEUTICALS INC (ONXX) Delisted | EVP, Chief Commercial Officer | 35,911 | — | — | -$4.40M | 14 | 2013-09-05 |
Recent Filings · Page 14 of 15
145 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2013-10-03 | — | Mixed | −35,911 | -$4.49M | |
| 2013-09-05 | ONYX PHARMACEUTICALS INC (ONXX) Delisted | Tax (F) | −2,099 | -$259.5K | EDGAR |
| 2013-08-14 | ONYX PHARMACEUTICALS INC (ONXX) Delisted | Mixed | −1,061 | -$898.5K | EDGAR |
| 2013-05-15 | ONYX PHARMACEUTICALS INC (ONXX) Delisted | Mixed | — | -$526.6K | EDGAR |
| 2013-04-03 | ONYX PHARMACEUTICALS INC (ONXX) Delisted | Sell (S) | −466 | -$40.1K | EDGAR |
| 2013-04-01 | ONYX PHARMACEUTICALS INC (ONXX) Delisted | Grant (A) | +8,600 | $0 | EDGAR |
| 2013-02-06 | ONYX PHARMACEUTICALS INC (ONXX) Delisted | Mixed | — | -$365.5K | EDGAR |
| 2012-11-30 | ONYX PHARMACEUTICALS INC (ONXX) Delisted | Mixed | −3,747 | -$619.4K | EDGAR |
| 2012-10-05 | ONYX PHARMACEUTICALS INC (ONXX) Delisted | Sell (S) | −2,314 | -$200.2K | EDGAR |
| 2012-09-06 | ONYX PHARMACEUTICALS INC (ONXX) Delisted | Sell (S) | −1,878 | -$136.7K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.